lunes, 16 de noviembre de 2026

FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics It’s a regulatory setback for Summit, though one that was not entirely unforeseen

https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/ By Adam FeuersteinNov. 15, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

No hay comentarios:

Publicar un comentario